PMID- 35116424
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220501
IS  - 2219-6803 (Electronic)
IS  - 2218-676X (Print)
IS  - 2218-676X (Linking)
VI  - 10
IP  - 2
DP  - 2021 Feb
TI  - Preintervention MCP-1 serum levels as an early predictive marker of tumor 
      response in patients with hepatocellular carcinoma undergoing transarterial 
      chemoembolization.
PG  - 966-976
LID - 10.21037/tcr-20-2791 [doi]
AB  - BACKGROUND: Transarterial chemoembolization (TACE) is a widely accepted treatment 
      for unresectable or intermediate-stage hepatocellular carcinoma (HCC). However, 
      response rates to TACE are heterogeneous and it is not fully understood which 
      patients benefit most from TACE therapy in terms of tumor response. To identify 
      the possible predictive roles of the perioperative monocyte chemoattractant 
      protein-1 (MCP-1) levels in patients of HCC treated with TACE. METHODS: Forty 
      patients of HCC receiving TACE were enrolled in a single center prospective 
      observational study. MCP-1 and miR-210 levels were measured in 40 HCC patients at 
      baseline before TACE and compared with 17 healthy controls by immunoassay and 
      reverse transcriptase quantitative polymerase chain reaction (RT-qPCR). Tumor 
      response assessments were taken after TACE treatment 4-6 weeks. Univariate and 
      multivariate analysis were conducted to analyze factors correlated with tumor 
      response in a Logistic regression model. The predictive roles of the involved 
      variables on tumor response in patients with HCC suffering TACE were examined by 
      receiver operating characteristic (ROC) curve analysis. RESULTS: The serum MCP-1 
      and miR-210 levels were significantly elevated in HCC patients compared to 
      healthy subjects. Patients with the low preintervention MCP-1 and miR-210 levels 
      attained a higher probability of achieving an objective response (OR) (88.5% 
      vs.42.9%, P=0.007; 76.9% vs. 35.7%, P=0.010, respectively). Pre-TACE MCP-1 level 
      (<816.63 pg/mL) was an independent risk factor associated with OR after TACE by 
      univariate and multivariate analysis while Pre-TACE miR-210 level (<4.43 relative 
      expression) was just positive by univariate analysis. ROC curve analysis showed 
      that a combined index based on those two factors exhibited optimal predictive 
      power of tumor response among all the involved variables (area under the curve 
      =0.823, 95% CI: 0.681-0.965). Additionally, high pre-TACE serum MCP-1 level was 
      correlated with cirrhosis, vascular invasion and Barcelona Clinic Liver Cancer 
      (BCLC) stage. Elevated pre-TACE serum miR-210 level was associated with and BCLC 
      stage. CONCLUSIONS: The study demonstrates that the pre-TACE serum MCP-1 level 
      serves as an effective predictor for tumor response. These findings probably help 
      discriminate HCC patients pre-TACE who specially benefit from TACE regarding OR.
CI  - 2021 Translational Cancer Research. All rights reserved.
FAU - You, Ran
AU  - You R
AD  - Department of Interventional Radiology, Jiangsu Cancer Hospital & Jiangsu 
      Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical 
      University, Nanjing, China.
FAU - Jiang, Hao
AU  - Jiang H
AD  - Department of Interventional Radiology, Jiangsu Cancer Hospital & Jiangsu 
      Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical 
      University, Nanjing, China.
FAU - Xu, Qingyu
AU  - Xu Q
AD  - Department of Interventional Radiology, Jiangsu Cancer Hospital & Jiangsu 
      Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical 
      University, Nanjing, China.
FAU - Yin, Guowen
AU  - Yin G
AD  - Department of Interventional Radiology, Jiangsu Cancer Hospital & Jiangsu 
      Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical 
      University, Nanjing, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Transl Cancer Res
JT  - Translational cancer research
JID - 101585958
PMC - PMC8797576
OTO - NOTNLM
OT  - Monocyte chemoattractant protein-1 (MCP-1)
OT  - hepatocellular carcinoma (HCC)
OT  - miR-210
OT  - transarterial chemoembolization (TACE)
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx. doi.org/10.21037/tcr-20-2791). The authors have no 
      conflicts of interest to declare.
EDAT- 2022/02/05 06:00
MHDA- 2022/02/05 06:01
PMCR- 2021/02/01
CRDT- 2022/02/04 05:48
PHST- 2020/08/26 00:00 [received]
PHST- 2020/12/04 00:00 [accepted]
PHST- 2022/02/04 05:48 [entrez]
PHST- 2022/02/05 06:00 [pubmed]
PHST- 2022/02/05 06:01 [medline]
PHST- 2021/02/01 00:00 [pmc-release]
AID - tcr-10-02-966 [pii]
AID - 10.21037/tcr-20-2791 [doi]
PST - ppublish
SO  - Transl Cancer Res. 2021 Feb;10(2):966-976. doi: 10.21037/tcr-20-2791.